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Abstract 
Background: General practitioners (GPs) frequently order blood tests when they see patients 
presenting with unexplained complaints. Due to the low prevalence of serious pathology in 
general practice, the risk of false-positive test results is relatively high. This may result in 
unnecessary further testing, leading to unfavourable effects such as patient anxiety, high costs, 
somatisation and morbidity. A policy of watchful waiting is expected to lower both the number of 
patients to be tested and the risk of false-positive test results, without missing serious 
pathology. However, many general practitioners experience barriers when trying to postpone 
blood testing by watchful waiting. The objectives of this study are (1) to determine the accuracy 
of blood tests in patients presenting with unexplained complaints in terms of detecting 
pathology, (2) to determine the accuracy of a watchful waiting strategy and (3) to determine the 
effects of a quality improvement strategy to promote the postponement of blood test ordering 
by GPs for patients with unexplained complaints. 
Design: General practices are randomised over three groups. Group 1 is instructed to order 
blood tests immediately, group 2 to apply a watchful waiting policy and group 3 also to 
postpone testing, but supported by our quality improvement strategy. The trial consists of two 
sub-studies: a diagnostic study at patient level (group 1 versus groups 2 and 3) and a quality 
improvement study at GP level (group 2 versus group 3). The diagnostic strategy to be used 
involves of both customary and innovative tests. The quality improvement strategy consists of 
two small-group meetings and a practice outreach visit. Patient follow-up ends at 12 months 
after the initial consultation. Primary outcome measures are the accuracy and added value of 
blood tests for detecting pathology, the effect of a 4-week postponement of test ordering on the 
blood test characteristics and the quantity of tests ordered. Secondary outcome measures are 
the course of complaints, quality of life, satisfaction with care, anxiety of patients and 
practitioners, determinants of physicians’ behaviour, health care utilisation and costs. 
Discussion: The innovative aspect of this trial is that it combines a clinical–epidemiological 
study and a quality of care study. 
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Background 
Unexplained Complaints 
‘Unexplained complaints’ can be defined as: those complaints for which a general practitioner 
(GP), after clarifying the reason for encounter, taking history and performing physical 
examination, is unable to establish a diagnosis.[1] This definition reflects a broad continuum of 
clinical pictures, ranging from complaints of recent onset to more chronic situations in which the 
physician is convinced that somatic disease is absent. Newly presented unexplained 
complaints will in most cases be self-limiting, but they can also develop into chronic complaints, 
or might be the first sign of serious disease.[2] Since GPs are usually the first health care 
professionals patients present their complaints to, these complaints belong to the particular 
expertise of GPs, who are used to deal with this type of complaints autonomously, without 
referring the patients to hospital.  
On average, 13% of consultations involve complaints considered unexplained by the GP.[3] 
Although only a small minority of these lead to chronicity or serious disease, additional 
diagnostic testing is often done after history taking and physical examination.[4, 5] 
 
Blood test ordering 
It has frequently been suggested that immediate test ordering in unexplained complaints is 
superfluous.[6-8] Since the pretest probability of serious pathology in patients with unexplained 
complaints is usually low, the risk of false-positive test results is relatively high. This may result 
in a chain of unnecessary further testing, which in turn might lead to patient anxiety, high costs, 
somatisation and a risk of serious side effects or even unnecessary morbidity.[9, 10] Applying a 
watchful waiting policy is recommended because the majority of these complaints are expected 
to be self-limiting. Patients in whom the complaints are not self-limiting will have a higher prior 
probability of having serious pathology, and the diagnostic accuracy of tests in this selected 
group is expected to be higher, because of the lower risk of false-positive test results.  
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We have found only one guideline on blood test ordering for unexplained complaints in general 
practice. This guideline, issued by the Dutch College of General Practitioners (NHG), 
recommends an initial watchful waiting strategy. If a complaint persists, it recommends ordering 
a limited number of tests (glucose, haemoglobin (Hb), erythrocyte sedimentation rate (ESR) 
and thyroid stimulating hormone (TSH)).[1, 11]  
However, these test recommendations are based on theory and consensus rather than on 
evidence. Moreover, in practice, more blood tests are ordered, or the watchful waiting strategy 
is not followed. Little is known about the accuracy or additional value of diagnostic blood tests 
or combinations of such tests, in addition to signs, symptoms and environmental and 
psychosocial factors, for the purpose of discriminating between self-limiting unexplained 
complaints and pathology. In addition, the accuracy of some newer tests, such as the 
carbohydrate deficient transferrin (CDT) test for the detection of pathology in patients with 
unexplained complaints in general practice, is not yet known.[12] Furthermore, several 
questions concerning the non-diagnostic effects of test ordering, e.g. on patient and doctor 
anxiety, remain unanswered. Apart from their diagnostic purposes, GPs frequently order tests 
for more strategic reasons, e.g. to prevent referral to a specialist or to make the psychosocial 
nature of complaints more acceptable to the patient, thereby anticipating normal blood test 
results.[11]  
 
Improvement of test ordering 
Though formal evidence is lacking, one can conclude from the high volume of tests ordered by 
GPs and the low probability of pathology that there is room for improvement to GPs’ blood test 
ordering behaviour for patients presenting with unexplained complaints.[13, 14] It is generally 
accepted that strategies to improve professionals’ behaviour need to be developed 
systematically, based on barriers to and facilitators of the target behaviour.[15] Determinants of 
blood test ordering by GPs for patients with unexplained complaints include not only a lack of 
knowledge about the diagnostic value of blood testing but also practice routines, GPs’ tolerance 
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of uncertainty, experienced pressure from patients, tactical motives and the perceived need to 
reassure patients.[11] This means that a strategy aimed at reducing test ordering by 
professionals should not only focus on improving diagnostic knowledge but also on skills such 
as dealing with uncertainty and patient pressure and applying alternative modes to reassure 
patients. The different types of objectives require adequate and tailored methods of instruction, 
e.g. teaching a skill requires practising rather than lecturing only. Since patients also seem to 
play a role in the decision process to order tests, it may be valuable to focus a strategy on 
patients as well, in order to achieve greater effects. 
 
Objectives of the study  
The first objective of the ongoing study presented here is to determine the accuracy of 
diagnostic blood tests or combinations of such tests and their value, in addition to signs, 
symptoms and contextual factors, for the purpose of discriminating between self-limiting 
diseases and serious pathology in patients presenting with unexplained complaints. The 
second objective is to compare the accuracy of a watchful waiting strategy with that of 
immediate test ordering. The third objective is to evaluate the effects of a systematically 
designed quality improvement strategy for GPs, aiming at the postponement of blood test 
ordering in patients with unexplained complaints.  
 
Research questions 
1. What is the course of complaints that are considered unexplained by GPs over a period 
of one year? 
2. What is the diagnostic accuracy of blood tests, relative to and in addition to combinations 
of signs and symptoms, for the purpose of discriminating between self-limiting 
complaints and early stages of pathology in patients presenting with unexplained 
complaints? 
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3. What is the cost-effectiveness of a 4-week watchful waiting policy compared to 
immediate test ordering in patients presenting with unexplained complaints? ‘Costs’ in 
this respect include direct medical costs, absence from work and immaterial costs such 
as patients’ uncertainty, satisfaction and quality of life. 
4. What is the cost-effectiveness of a systematically developed strategy to improve GPs’ 
test ordering behaviour, compared to merely instructing them to postpone testing? 
 
Cooperation 
The departments of General Practice of the University of Maastricht and of the Academic 
Medical Center-University of Amsterdam are cooperating in this study. Data collection ended 
on December 31, 2004. At the time of writing of this protocol article, we are engaged in data 
cleaning and analysis. 
 
Ethical approval and informed consent procedure 
Ethical approval 
The medical ethics committees of both the Academic Medical Center-University of Amsterdam 
and the University Hospital Maastricht have approved the study. 
 
Informed consent procedure 
GPs hand out written information and an informed consent form to eligible patients. Patients 
are given the opportunity to read the information and think about participation before signing 
the consent form. Patients in group 1 are fully informed about the trial. Patients in groups 2 and 
3 are kept naive about the possibility of immediate blood test ordering. This is because it is 
impossible to blind patients for the test group they are in (immediate or postponed blood test 
ordering). Bias could be caused by selective dropout of patients and by a Hawthorne effect, as 
patients can be expected to prefer immediate test ordering over a watchful waiting policy. 
 7
Patients in groups 2 and 3 are told that the study investigates the way their GPs manage 
patients with unexplained complaints. 
 
Design 
Operationalisation of ‘unexplained complaints’ 
Of the complaints that are considered unexplained by GPs according to the definition drawn up 
by the Dutch College of General Practitioners (NHG), the following 5 were selected: fatigue, 
abdominal complaints, musculoskeletal complaints, itch and weight changes. These were 
selected on the basis of the following criteria: commonly seen unexplained complaints in 
general practice, frequent ordering of blood tests and the possibility that clinically relevant 
underlying diseases are detected by blood tests.  
 
Clustered randomised clinical trial 
Participating general practices are randomised over 3 groups (figure 1). GPs in group 1 are 
instructed to order blood tests immediately at the first consultation. Those in group 2 are 
instructed to restrict blood test ordering to patients with complaints persisting after four weeks. 
GPs in group 3 are also instructed to try and postpone test ordering, but they also participate in 
a quality improvement strategy that supports them in postponing test ordering for patients with 
unexplained complaints. The study design includes two sub-studies. The first is a diagnostic 
study comparing patients from group 1 (immediate test ordering) with patients from groups 2 
and 3 (4 weeks of watchful waiting). The second is a quality improvement study, comparing 
group 2 (instruction to postpone test ordering) with group 3 (instruction to postpone test 
ordering plus quality improvement strategy) in terms of the actual postponement of test 
ordering. 
The reason why we decided to randomise general practices instead of patients or individual 
GPs is that we assumed there would be contamination, for three reasons. Firstly, it is not 
possible for GPs to selectively use the communication skills they have learnt during the quality 
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improvement strategy in one patient and fall back to their previous behaviour in the next 
patient. Secondly, in group practices, patients are sometimes seen by different colleagues at 
different appointments. If these GPs are in different intervention arms, this may bias the results. 
Thirdly, patients of different GPs within one practice may exchange experiences about the 
scientific research project they participate in. The randomisation procedure is carried out 
separately for the two regions where the participatinjg university departments are located. To 
achieve allocation concealment, study groups are assigned to GPs by a random number seed 
computer program that randomises in blocks and is operated by an experienced research 
assistant. 
 
Procedure 
If, after history taking and physical examination, a patient is considered to have unexplained 
complaints and gives informed consent, the GP enrols the patient in the study. Depending on 
the GP’s study arm, blood test ordering or a 4-week watchful waiting policy is suggested to the 
patient. All patients are asked to return to the GP if complaints do not disappear within 4 weeks. 
If patients return, blood tests are ordered for every patient, irrespective of GPs’ study arm. This 
means that patients in group 1 are then tested for the second time and patients in groups 2 and 
3 for the first time. 
 
All tests are performed at the regional laboratory, according to local standard operating 
procedures and using the local reference values. 
 
Patient follow-up ends at 12 months after the initial consultation. 
 
Power calculation 
Based on previous research, we estimated that approximately 2 percent of patients will 
eventually be diagnosed with serious pathology.[16] We estimated that 100 patients with 
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pathology will be needed to allow valid conclusions, which means that 5000 patients should be 
included in the study. Dutch GPs see approximately 500 patients a month, of whom 1–5% are 
estimated to have unexplained complaints. This means that each GP could on average include 
180 patients in one year. These figures mean that we need 27 GPs to participate. Assuming a 
patient refusal rate of approximately 50 percent, 54 GPs need to be recruited. A total of 5000 
patients (approximately 1700 in each study group) would also be sufficient to determine the 
costs and effects of the quality improvement strategy with enough precision. 
  
Participants  
The project is being carried out in a two regions in the Netherlands, one in the south and one in 
the west. 
 
GPs 
For logistic reasons, only GPs associated with certain laboratories for the handling of their test 
requests can participate in the trial. These laboratories are situated in the western (Haarlem, 
Almere) and southern (Sittard, Weert, Geldrop, Eindhoven, Helmond, Veldhoven, ’s 
Hertogenbosch) regions. No further GP participation criteria were formulated. 
 
Patients 
Patients aged 18 years and older, presenting with one of the unexplained complaints 
mentioned above, who have not consulted their GPs for this complaint in the previous 6 months 
and who are able to speak, read and write Dutch are eligible to be included in the study. GPs 
decide to ask patients to participate in the study after history taking and physical examination, 
so the decision to label the complaints of a patient as unexplained is made entirely by the GPs. 
Excluded are patients with unexplained complaints for whom the GPs feel that watchful waiting 
would be unacceptable to them. Patients are asked to participate by their GPs. The GPs are 
asked to enrol each consecutive eligible patient. 
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Blinding 
Researchers 
The researchers are not blinded for the trial group allocation of the participating GPs. They are 
not involved in the GPs’ decision to label patients as having unexplained complaints, nor in the 
test ordering procedure or the reporting of the results of the laboratory tests. 
 
GPs 
The GPs are not blinded for the trial group they are randomised to, but they are for the content 
and format of the quality improvement strategy that aims to support GPs in postponing test 
ordering. In addition, only those test results from the set of tests we decided to include in the 
study (see the section entitled 'Diagnostic intervention at patient level' below) they ordered 
themselves are fed back to them, so they are partially blinded to the test results. Since the 
effects of test results on the treatment given to patients and on their clinical course are outcome 
measures of our study, we do not aim at complete blinding to the test results.  
 
Patients 
Patients in group 1 are fully informed about the blood testing options, whereas patients from 
groups 2 and 3 are kept naive about the possibility of getting blood tests ordered. All patients 
are blinded for the possibility that their GP is participating in a quality improvement strategy. In 
our opinion, full blinding is not possible because there is no placebo for blood testing that is 
feasible and ethically acceptable.  
 
Laboratories 
Laboratories are blinded for all patient characteristics except sex and age. 
 
Diagnostic intervention at patient level 
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Selection of blood tests 
Members of an expert panel including GPs and hospital specialists (n = 20) have been 
individually asked to propose tests which they regarded as useful diagnostic tools in general 
practice for each of the 5 complaints. All tests mentioned at least twice were included in a 
complaint-specific set of tests (table 1). If not already included in the set, the four tests 
recommended in the NHG guideline (glucose, ESR, TSH and Hb) were added. In addition, iron 
parameters (transferrin saturation (TS) and ferritin), anti-endomysium and carbohydrate 
deficient transferrin (CDT) were added as indicators of haemochromatosis, celiac disease and 
alcohol abuse respectively. These three diseases can lead to unexplained complaints, are 
frequently missed by GPs according to the literature and should be demonstrable with the 
above blood tests. The diagnostic accuracy of these tests in patients presenting with 
unexplained complaints in general practice has, however, not yet been established.[12, 17-20] 
 
Immediate blood test ordering 
GPs from group 1 are instructed to order blood tests immediately when including a patient in 
the study. The GPs are free to decide on the number and type of blood tests. The patient takes 
the blood test ordering form to the regional laboratory participating in the study. At the 
laboratory, the tests ordered by the GP are supplemented by the complaint-specific tests from 
the sets described in table 1. Only results of tests ordered by the GPs themselves are fed back. 
If a GP does not intend to order any tests (but is obliged to do so by the study protocol), the 
results of the four tests recommended by the NHG guideline are fed back, because patients 
expect results after a blood sample has been taken. 
 
Watchful waiting for 4 weeks 
GPs from groups 2 and 3 propose to the patients they include to observe a 4-week watchful 
waiting policy. When watchful waiting is not considered feasible by the GP, e.g. because a 
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patient insists on being tested, test ordering is allowed. In that case, the GPs are asked to state 
the reasons for not postponing test ordering on a special form. 
 
Reference standard 
The nature of unexplained complaints implies that no proper gold standard exists. Hence, we 
opted for a delayed type cross-sectional study design.[21, 22] In this type of design, the 
diagnosis after the 12-month follow-up period is used as a reference standard. This diagnosis is 
established separately by two researchers, making use of information from the GPs’ patient 
records. Differences are discussed and consensus is sought. If consensus cannot be reached, 
the case is presented to an expert panel that takes the final decision. No restrictions are 
imposed on GPs as to patient management during follow-up. 
 
Quality improvement strategy  
Development of the strategy 
Determinants of blood test ordering for unexplained complaints – both those relating to the GPs 
and those relating to the patients – have been identified previously.[11, 23] Based on these 
determinants, a quality improvement strategy has been developed using a systematic 
procedure based on intervention mapping techniques.[15] The strategy has been pilot-tested, 
after which slight adjustments were made based on the pilot results. 
 
Content of quality improvement strategy 
For each GP in group 3, the strategy consists of two small-group meetings and one outreach 
visit by the researchers to their practice. Table 2 provides more details on the content of the 
strategy. The first group meeting is led by a GP experienced in medical diagnostic decision-
making and a behavioural scientist experienced in teaching communication skills, while the 
second meeting is tutored only by the behavioural scientist. The outreach practice visit is made 
by one of the researchers. We have also developed patient education leaflets and diaries, to be 
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handed out by the GPs, and a video message about watchful waiting, to be shown in the 
waiting room. All materials have been developed by the research team. 
 
Procedure 
At the beginning of the trial, all GPs in group 3 are invited to the small group meetings, which 
are organised regionally, usually at the regional hospital. These meetings are held with an 
interval of approximately four weeks. After these meetings, an appointment is made for the 
practice visit, which takes place at least 3 months after the second group meeting. GPs are 
encouraged to prepare for the meetings by doing homework assignments. 
 
Control group 
GPs in group 2 are the control group for GPs in group 3. In order to ensure a maximum 
contrast, no strategy is offered to group 2. 
 
Measurements 
All measurement instruments, measurement times and variables are summarised in table 3. 
Most questions in the questionnaires have been formulated by the research team, based on 
topics found in the literature. Quality of life is measured by the RAND SF36, together with the 
thermometer of the Euroqol questionnaire. Both are widely used and have been validated 
extensively.[24-26]  
 
Patients 
Findings of history taking and physical examination are recorded on a prestructured complaint 
registration form by the GP after the consultation(s). 
All patients are given the first questionnaire at the first consultation and a second questionnaire 
at the second consultation after 4 weeks. Patients who do not return to their GP after 4 weeks 
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are sent a questionnaire by mail. Patients from all groups receive follow-up questionnaires by 
mail at 6 and 12 months after the initial consultation. 
After 12 months, i.e. at the end of the follow-up period, data on the final diagnosis and health 
care consumption are collected from the patients’ records by the researchers (MB and HK). 
Copies of test ordering and result forms are collected by the researchers (MB and HK) from the 
regional laboratories. 
 
GPs 
Background data of all participating GPs are collected before the start of the patient inclusion 
process. Data on whether the GPs are satisfied with the consultation, whether they suspect 
serious pathology and whether they are certain about the diagnosis are collected from the 
complaint registration form. The GPs’ test ordering behaviour is derived from the test ordering 
forms and the patient records. GPs in group 3 are asked to complete evaluation forms on 
process items of the quality improvement strategy. In addition, the determinants of their change 
processes they mentioned are audiotaped during the practice visit that is part of the quality 
improvement strategy. 
 
Data analysis 
Primary outcome measures of the diagnostic intervention 
The first primary outcome is the accuracy and added value of blood tests in detecting serious 
pathology (per test and in combinations relevant to general practice), related to and in addition 
to signs and symptoms. Serious pathology is defined as pathology requiring treatment. The 
second primary outcome is the effect of a 4-week postponement of test ordering on the blood 
test characteristics. 
 
Primary outcome measures of the quality improvement strategy 
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The primary outcome of the quality improvement strategy is the quantity of tests ordered in 
relation to the instruction to either order blood tests immediately or to suggest a 4-week 
watchful waiting policy. 
 
Secondary outcome measures 
The secondary outcome measures are summarised in table 4. 
 
Types of analysis 
An intention-to-postpone analysis will be performed. Longitudinal comparisons will be made 
using repeated measurements techniques and multilevel analysis to correct for potential 
clustering of outcomes in GPs and practices. Barriers to and facilitators of change are analysed 
qualitatively.  
 
Non-inclusion analysis 
A non-inclusion analysis will be performed to check whether included patients are comparable 
to patients who are eligible but not included. 
 
Discussion 
Reasons for publishing this study design 
This protocol describes an RCT which combines the generation of new clinical and 
epidemiological evidence to underpin guidelines on test ordering in unexplained complaints 
with the implementation of these guidelines. To our knowledge, this is the first RCT to integrate 
questions on clinical epidemiology and quality of care. The first reason for us to opt for this 
combination is that it meets suggestions made in the literature to evaluate the value of 
diagnostic tests just as rigorously as is done with treatments, namely by RCTs, and to pay 
attention to the implementation of evidence while generating it.[27] Secondly, both sub-studies 
require large numbers of participants with the same characteristics, and combining the two 
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increases the efficient use of available resources. Apart from the advantages of the 
combination, however, we also need to mention one methodological disadvantage. Ideally, the 
evidence on which a quality improvement strategy is based should already be available at the 
start of development of the strategy, as it might influence its format. In the case of this study, 
evidence generation on one hand and the design and execution of the strategy on the other run 
in parallel. Evaluation at the end of the study should clarify whether the new evidence will 
necessitate alterations in either the diagnostic guidelines or the quality improvement strategy.  
General reasons to publish the design of a study before the analyses have begun have been 
discussed by Godlee and De Bruijn et al.[28, 29] In the case of the present study, there was an 
additional reason to do so. The design of the study presented here is rather complicated 
because, due to the nature of unexplained complaints, we had to seek methodological solutions 
that were not always straightforward.[22] By presenting the decisions made in designing this 
study, we are hoping to start a debate on proper methodology for research into unexplained 
complaints. 
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Figure 1. Randomisation scheme   
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Tables and captions 
Table 1. Sets of laboratory tests per complaint 
 
Fatigue Abdominal 
complaints 
Musculo- 
skeletal 
complaints 
Weight 
changes 
Itch 
Alkaline Phosphatase (AF) x x  x  
Alanine aminotransferase (ALAT) x x  x x 
Amylase  x  x  
Anti-endomysium  x  x  
Aspartate aminotransferase (ASAT) x x  x  
Bilirubin     x 
Erythrocyte sedimentation rate (ESR) x x x x x 
Carbohydrate-deficient transferrin (CDT) x x  x x 
Creatinin kinase (CK)   x   
Creatinin x x x x x 
C-reactive protein (CRP)  x    
Differentiated leukocyte count x x  x x 
Eosinophils     x 
Ferritin x x x x  
Gamma glutamyl transferase (GGT) x x  x x 
Glucose x x x x x 
Haemoglobin (Hb) x x x x x 
Potassium (K) x  x   
Latex fixation test    x   
Lactate dehydrogenase (LDH) x   x  
Leukocyte count x x  x x 
Monosticon x     
Total IgE  x   x 
Thyroid stimulating hormone (TSH) x x x x x 
Transferrin saturation (TS) x x x x  
Urea     x 
Uric acid   x   
Total number of tests 17 18 11 17 14 
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 Table 2. Elements of the quality improvement strategy 
 
Elements of strategy 
Contents of programme Small group meeting 1 
Part 1: Interactive explanation of diagnostic value of diagnostic testing 
for unexplained complaints and effect of watchful waiting policy on 
diagnostic value. 
Part 2: Discussion of difficulties experienced in practice when dealing 
with patients presenting with unexplained complaints. 
Goal setting to change behaviour in GPs’ own practice. 
Small group meeting 2 
Part 1: Discussion about experiences with behaviour change. Searching 
for solutions to barriers that have arisen. 
Part 2: Practicing difficult situations by means of video vignettes. 
Setting new goals to change own behaviour. 
Practice visit 
Discussing individuals’ barriers to change and providing suggestions to 
overcome these, based on stage of change. 
 
In between meetings, GPs get the opportunity to work on their goals to 
change their behaviour. 
Materials - Course book. 
- Leaflets for patients with information about unexplained 
complaints. 
- Diaries about complaints and food intake to hand out to patients 
to fill in and later discuss together. 
- Video message for the waiting room, explaining the use of 
watchful waiting. 
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Table 3. Instruments and variables 
 
Instrument  
 
Variables Time points Population Method 
  T0 T1# T 1.5# T6 T12  - Provision 
- Person who  
  completes  
  questionnaire 
(- Comments) 
GPs’ background 
data  
Personal data 
Practice characteristics 
CME 
Laboratory facilities  
available in practice 
x 
x 
x 
x 
 
    All GPs - By mail 
- GP 
Complaint 
registration form 
(for each individual 
type of complaint) 
Symptoms 
Signs 
Working hypothesis 
Degree of 
unexplainedness 
Degree of suspicion of  
serious pathology 
Degree of insecurity of GP 
Satisfaction of GP 
x 
x 
x 
x 
 
x 
 
x 
 
x 
x 
x 
x 
x 
 
x 
 
x 
 
x 
   All patients - Present in practice 
- GP 
Patients’ back-
ground data  
(included in patient 
questionnaire) 
Date of birth 
Country of birth 
Sex 
Marital status 
Type of health insurance 
Level of education 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
All patients - Handed out by GP  
  (T0, T1) 
- By mail (T1.5-T12) 
- Patient 
Patient 
questionnaire 
Intensity of complaints 
Course of complaints 
Satisfaction with care 
Anxiety 
Quality of life  
- RAND 36 
- Euroqol thermometer 
Utilisation of health care 
x 
x 
x 
x 
x 
 
 
x 
x 
x 
x 
x 
x 
 
 
x 
x 
x 
 
 
x 
 
 
x 
x 
x 
 
 
x 
 
 
x 
x 
x 
 
 
x 
 
 
x 
All patients - Handed out by GP   
  (T0, T1) 
- By mail (T1.5-T12) 
- Patient 
Test ordering form Quality of test ordering 
Quantity of test ordering 
x* 
x 
x* 
x 
   All patients - Present in practice 
- GP 
Test result form Test results 
 
x* x*    All patients - Laboratory 
- Laboratory staff 
 
Record 
examination form 
Final diagnosis 
Utilisation of health care 
Use of watchful waiting 
strategy 
    x 
x 
x 
All patients - Practice/university 
- Researcher 
  
Meeting 1 Meeting 2 Practice 
visit 
  
Reports of small 
group meetings 
Participation 
Learning effects 
x 
x 
x 
x 
 All GPs in  
intervention  
group 
- Meeting room 
- Researcher 
Evaluation forms 
of small group 
meetings 
Valuation of programme 
Learning effects 
Suggestion for 
improvement 
x 
x 
x 
x 
x 
x 
 All GPs in  
intervention  
group 
- Meeting room 
- Researcher 
GP interview in 
practice 
Barriers and facilitators  
during change 
Stages of change 
  x 
 
x 
All GPs in  
intervention  
group 
- Practice 
- GP 
Cost registration Costs of development and 
organising of strategy 
x x x  - University 
- Researcher 
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Legend for table 3 
* T0 for patients randomised to group 1, T1 for all patients but only if they revisit their GP 
#  T1 is the time point to measure a follow-up visit by the patient 4 weeks after inclusion. If a 
patient does not return to the GP, a questionnaire is sent by mail after 6 weeks. This time 
point is indicated as T1.5.
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Table 4 Secondary outcome measures 
Incidence of unexplained complaints in general practice 
Predictive value of GPs’ working hypothesis 
Duration of unexplained complaints 
Effect of unexplained complaints on patients’ quality of life 
Effect of immediate testing or watchful waiting on patients’ satisfaction with care, anxiety, 
medical consumption and sick leave 
Effect of immediate testing or watchful waiting on GPs’ satisfaction, anxiety and insecurity 
Effect of quality improvement strategy on GPs’ knowledge about the value of blood test 
ordering in unexplained complaints, communication skills and attitudes 
Barriers to and facilitators of GPs proposing a watchful waiting strategy 
Costs of the quality improvement strategy 
 
 randomisation 
Group 3 
Four weeks of watchful 
waiting 
Participation in 
intervention 
Group 2 
Four weeks of watchful 
waiting 
Group 1 
Immediate blood test 
ordering 
Patient does not return to 
GP (T1.5) 
Questionnaire by mail 
Patient inclusion 
Questionnaire via GP 
GP in intervention 
Patient returns to GP (T1) 
Questionnaire via GP 
Blood test ordering 
Patient inclusion 
Questionnaire via GP 
Follow-up 
Questionnaire by mail 
Follow-up 
Questionnaire by mail 
Final diagnosis 
Patient inclusion 
Questionnaire via GP 
Blood test ordering  
Participating GPs 
T0 
1 month 
6 months 
12 months 
Figure 1
